EDRS
STML

Edmond de Rothschild (Suisse)’s Stemline Therapeutics, Inc. STML Stock Holding History

Edmond de Rothschild (Suisse)’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-30,000
Closed -$265K – 454
2015
Q3 		$265K Hold
30,000
– – 0.09% 131
2015
Q2 		$353K Buy
+30,000
New +$417K 0.11% 125

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Edmond de Rothschild (Suisse)'s STML Position: Q4 2015 in Review

Edmond de Rothschild (Suisse) sold out of Stemline Therapeutics, Inc. (STML) in Q4 2015, closing a stake of 30,000 shares — an estimated $265K sold.

Edmond de Rothschild (Suisse) first reported a position in STML in Q2 2015 and held it in 2 quarters. The position peaked at $353K in Q2 2015. 66 funds tracked by Wall St. Rank hold STML as of Q4 2015.

  • Edmond de Rothschild (Suisse) reported no remaining Stemline Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Edmond de Rothschild (Suisse) sold 30,000 Stemline Therapeutics, Inc. shares in Q4 2015, an estimated $265K.
  • Edmond de Rothschild (Suisse) first reported a position in Stemline Therapeutics, Inc. in Q2 2015 and held it in 2 quarters.
  • Edmond de Rothschild (Suisse)'s Stemline Therapeutics, Inc. position peaked at $353K in Q2 2015.
  • 66 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2015.

Based on Edmond de Rothschild (Suisse)'s 13F filing for Q4 2015, filed 16 Feb 2016.